Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELTA 1: Phase 3 trial of delgocitinib cream in moderate to severe chronic hand eczema
2020-002960-30Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic hand dermatitis (CHE) comparing Delgocitinib cream 20 mg/g twice daily with Cream vehicle twice daily (2 arms). Started May 2021; status: completed.
02
Drugs
delgocitinib
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on 2020-002960-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002960-30.